Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 5

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

Authors Uy, Juanito, Fogelfeld L, Yannis G

Received 26 September 2011

Accepted for publication 7 November 2011

Published 10 January 2012 Volume 2012:5 Pages 1—10

DOI https://doi.org/10.2147/DMSO.S15404

Review by Single-blind

Peer reviewer comments 2


J Uy, L Fogelfeld, Y Guerra
Division of Endocrinology, Diabetes and Metabolism, John H Stroger Jr Hospital of Cook County, Chicago; Department of Endocrinology, Diabetes and Metabolism, Rush University Hospital, Chicago, IL, USA

Abstract: We have now at our disposal the new rapid-acting insulin analogs, of which insulin lispro was the first to become commercially available. While the differences in pharmacokinetic and pharmacodynamic characteristics are indisputable, the clinical benefits attained by these changes have not been as clear. In the present review, we discuss the structure, pharmacology, and landmark studies related to insulin lispro. The clinical characteristics of insulin lispro are compared with those of insulin regular and other insulin analogs in different clinical situations. Also included are the aspects of quality of life and cost-effectiveness that may modify the modern practitioner's decision to adopt one type of insulin over another.

Keywords: insulin lispro, rapid-acting, insulin, analog

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]